Sequencing Of Agents And Combination of Treatment Options for Renal Cell Carcinoma

Co-Host: Brian M. Shuch, MD At the conclusion of these activities, participants will be able to: 1. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer. 2. Explain best practices in RCC patient selection for various treatment options CME Available: https://auau.auanet.org/node/26099 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma